Arvinas up after early-stage trial shows drug lowers key Parkinson's marker

Arvinas

18/03/2026 11:18

** Shares of biotech firm Arvinas ARVN.O rise 2% to $12.22 premarket

** Co says its experimental drug ARV-102 reduced markers linked to Parkinson's - a progressive brain disorder affecting movement, memory and sleep - in a small, early-stage trial

** Adds the once-daily pill cut levels of LRRK2, a protein that builds up in Parkinson's patients' spinal fluid, by about half in 28 days

** Says the trial also showed reductions in markers associated with inflammation and cell damage, linked to Parkinson's disease and the rare, rapidly progressive brain disorder PSP

** Adds no serious side effects were reported and all adverse events were mild

** Co plans to start a new trial for PSP in the second quarter of 2026, pending regulatory feedback

** ARVN shares up 1.26% YTD vs. a ~38% decline in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))